Comparing Xcorporeal (OTCMKTS:XCRP) and Sight Sciences (NASDAQ:SGHT)
by Michael Walen · The Markets DailyXcorporeal (OTCMKTS:XCRP – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Earnings and Valuation
This table compares Xcorporeal and Sight Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xcorporeal | N/A | N/A | N/A | N/A | N/A |
| Sight Sciences | $77.36 million | 3.69 | -$38.43 million | ($0.71) | -7.38 |
Xcorporeal has higher earnings, but lower revenue than Sight Sciences.
Analyst Ratings
This is a breakdown of current ratings and price targets for Xcorporeal and Sight Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xcorporeal | 0 | 0 | 0 | 0 | 0.00 |
| Sight Sciences | 1 | 3 | 5 | 0 | 2.44 |
Sight Sciences has a consensus target price of $8.14, indicating a potential upside of 55.42%. Given Sight Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe Sight Sciences is more favorable than Xcorporeal.
Profitability
This table compares Xcorporeal and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xcorporeal | N/A | N/A | N/A |
| Sight Sciences | -46.83% | -52.34% | -28.49% |
Insider & Institutional Ownership
55.5% of Sight Sciences shares are held by institutional investors. 28.9% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Sight Sciences beats Xcorporeal on 6 of the 9 factors compared between the two stocks.
About Xcorporeal
Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.